Eloi Franco Trepat

Eloi Franco Trepat professional career started in oncology therapeutics (Hospital Sant Pau; Spain), cell fate modulation (CSIC-IRTA-CRAG; Spain), and stem cell microenvironment (RIKEN; Japan). Later, he became the first founding member of the Musculoskeletal Pathology Group (Institute IDIS-CHUS) led by Dr. Rodolfo Gómez Bahamonde. He primarily acted as predoctoral & postdoctoral researcher and secondarily as project and laboratory manager. Eloi F.T. led several research lines focused on blocking Toll-Like Receptors (TLRs) and inhibit the innate immune response in autoinflammatory & autoimmune diseases. Additionally, he co-led biomaterial, stem cell dynamics, and natural product research lines.

His interest in antivirals and immunomodulators started during the SARS-CoV-2 and extended to other emergent viruses after living in Serekunda (The Gambia). He has joined the Pathogen Immunity, Signalling and Therapeutic Applications (PISTA) group led by Dra. Nuria Izquierdo Useros to contribute designing new therapeutic tools against emerging pathogens.